172 related articles for article (PubMed ID: 21819451)
1. Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow-up.
Ahmed AR; Gürcan HM
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1074-83. PubMed ID: 21819451
[TBL] [Abstract][Full Text] [Related]
2. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C
J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
Sami N; Letko E; Androudi S; Daoud Y; Foster CS; Ahmed AR
Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of rituximab-intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy.
Oktem A; Akay BN; Boyvat A; Kundakci N; Erdem C; Bostancı S; Sanli H; Kocyigit P
J Dermatolog Treat; 2017 Feb; 28(1):50-54. PubMed ID: 27161164
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease.
Hashimoto T; Ishii N; Ohata C; Furumura M
J Pathol; 2012 Sep; 228(1):1-7. PubMed ID: 22692770
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatment for epidermolysis bullosa acquisita.
Engineer L; Ahmed AR
J Am Acad Dermatol; 2001 May; 44(5):818-28. PubMed ID: 11312431
[TBL] [Abstract][Full Text] [Related]
7. Epidermolysis bullosa acquisita: diagnosis by fluorescence overlay antigen mapping and clinical response to high-dose intravenous immunoglobulin.
Campos M; Silvente C; Lecona M; Suárez R; Lázaro P
Clin Exp Dermatol; 2006 Jan; 31(1):71-3. PubMed ID: 16309488
[TBL] [Abstract][Full Text] [Related]
8. Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins.
Gourgiotou K; Exadaktylou D; Aroni K; Rallis E; Nicolaidou E; Paraskevakou H; Katsambas AD
J Eur Acad Dermatol Venereol; 2002 Jan; 16(1):77-80. PubMed ID: 11952298
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
[TBL] [Abstract][Full Text] [Related]
10. [Epidermolysis bullosa acquisita: literature review].
Le Roux-Villet C; Prost-Squarcioni C
Ann Dermatol Venereol; 2011 Mar; 138(3):228-46. PubMed ID: 21397153
[TBL] [Abstract][Full Text] [Related]
11. Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases.
Kim JH; Kim YH; Kim SC
Acta Derm Venereol; 2011 May; 91(3):307-12. PubMed ID: 21394418
[TBL] [Abstract][Full Text] [Related]
12. [Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita].
Cavailhes A; Balme B; Gilbert D; Skowron F
Ann Dermatol Venereol; 2009 Nov; 136(11):795-9. PubMed ID: 19917432
[TBL] [Abstract][Full Text] [Related]
13. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
Sami N; Qureshi A; Ahmed AR
Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
[TBL] [Abstract][Full Text] [Related]
14. Epidermolysis bullosa acquisita: what's new?
Ishii N; Hamada T; Dainichi T; Karashima T; Nakama T; Yasumoto S; Zillikens D; Hashimoto T
J Dermatol; 2010 Mar; 37(3):220-30. PubMed ID: 20507385
[TBL] [Abstract][Full Text] [Related]
15. Autoimmunity to type VII collagen: epidermolysis bullosa acquisita.
Remington J; Chen M; Burnett J; Woodley DT
Curr Dir Autoimmun; 2008; 10():195-205. PubMed ID: 18460887
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.
Iwata H; Vorobyev A; Koga H; Recke A; Zillikens D; Prost-Squarcioni C; Ishii N; Hashimoto T; Ludwig RJ
Orphanet J Rare Dis; 2018 Sep; 13(1):153. PubMed ID: 30180870
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and Comparison of Clinical and iLaboratory Characteristics of Patients With IgA Epidermolysis Bullosa Acquisita, Linear IgA Bullous Dermatosis, and IgG Epidermolysis Bullosa Acquisita.
Becker M; Schumacher N; Schmidt E; Zillikens D; Sadik CD
JAMA Dermatol; 2021 Aug; 157(8):917-923. PubMed ID: 34160564
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid.
Sami N; Bhol KC; Razzaque Ahmed A
Clin Immunol; 2002 Jan; 102(1):59-67. PubMed ID: 11781068
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
[TBL] [Abstract][Full Text] [Related]
20. Management of epidermolysis bullosa acquisita.
Intong LR; Murrell DF
Dermatol Clin; 2011 Oct; 29(4):643-7. PubMed ID: 21925011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
